Literature DB >> 30344779

Sodium Iodide Symporter (NIS) in the Management of Patients with Thyroid Carcinoma.

June-Key Chung1, Hyun Woo Kim1, Haewon Youn1, Gi Jeong Cheon1.   

Abstract

Although radioiodine has been applied in thyroid diseases including carcinoma for over 70 years, it was only in 1996 that the basic molecular mechanism of iodine uptake was identified. Iodide is actively transported into the thyroid via a membrane glycoprotein known as sodium iodide symporter (NIS). NIS mediates radioiodine uptake into thyroid normal and cancer cells. The knowledge on NIS expression has provided scientific background to the empirical management of thyroid carcinoma. Based on recent studies of the NIS gene, this paper provides current clinical applications and future studies.

Entities:  

Keywords:  Gene therapy; NIS; Sodium iodide symporter; Theranostics; Thyroid cancer

Year:  2018        PMID： 30344779      PMCID： PMC6177348          DOI： 10.1007/s13139-018-0540-y

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  13 in total

Review 1.  Overview of the management of differentiated thyroid cancer.

Authors:  Jyotika K Fernandes; Terry A Day; Mary S Richardson; Anand K Sharma
Journal:  Curr Treat Options Oncol       Date:  2005-01

2.  Relationship between expression of the sodium/iodide symporter and (131)I uptake in recurrent lesions of differentiated thyroid carcinoma.

Authors:  J J Min; J K Chung; Y Lee; J Jeong; D Lee; J Jang; M Lee; B Cho
Journal:  Eur J Nucl Med       Date:  2001-05

3.  Expression of sodium-iodide symporter and TSH receptor in subclinical metastatic lymph nodes of papillary thyroid microcarcinoma.

Authors:  Yoon Kyoung So; Young-Ik Son; Chung-Hwan Baek; Han-Sin Jeong; Man Ki Chung; Young-Hyeh Ko
Journal:  Ann Surg Oncol       Date:  2011-08-31       Impact factor: 5.344

4.  Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.

Authors:  Elliot Sampson; James D Brierley; Lisa W Le; Lorne Rotstein; Richard W Tsang
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

5.  Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake.

Authors:  C A Fernández; M Puig-Domingo; F Lomeña; M Estorch; V Camacho Martí; A L Bittini; M Marazuela; J Santamaría; J Castro; P Martínez de Icaya; I Moraga; T Martín; A Megía; M Porta; D Mauricio; I Halperin
Journal:  J Endocrinol Invest       Date:  2009-03       Impact factor: 4.256

6.  Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma.

Authors:  Sungeun Kim; June-Key Chung; Hae-Sook Min; Joo-Hyun Kang; Do Joon Park; Jae Min Jeong; Dong Soo Lee; Sung-Hwae Park; Bo Youn Cho; Sinae Lee; Myung Chul Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-01-25

7.  Codon-optimized human sodium iodide symporter (opt-hNIS) as a sensitive reporter and efficient therapeutic gene.

Authors:  Young-Hwa Kim; Hyewon Youn; Juri Na; Kee-Jong Hong; Keon Wook Kang; Dong Soo Lee; June-Key Chung
Journal:  Theranostics       Date:  2015-01-01       Impact factor: 11.556

8.  Lesionalized therapy beyond personalized therapy in cancer management.

Authors:  June-Key Chung; Mi Jeong Kim; Hyewon Youn
Journal:  J Korean Med Sci       Date:  2014-10       Impact factor: 2.153

9.  Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.

Authors:  Jandee Lee; Kuk Young Nah; Ra Mi Kim; Yeon-Ju Oh; Young-Sil An; Joon-Kee Yoon; Gwang Il An; Tae Hyun Choi; Gi Jeong Cheon; Euy-Young Soh; Woong Youn Chung
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

Review 10.  Radioiodine therapy in differentiated thyroid cancer: the first targeted therapy in oncology.

Authors:  June-Key Chung; Gi Jeong Cheon
Journal:  Endocrinol Metab (Seoul)       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.